<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part5">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>5</PartID>
        <PartNumber>Part IV</PartNumber>
        <PartSequenceNumber>5</PartSequenceNumber>
        <PartTitle>Bone Metastasis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap25" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>25</ChapterID>
          <ChapterNumber>Chapter 25</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_25</ChapterDOI>
          <ChapterSequenceNumber>25</ChapterSequenceNumber>
          <ChapterTitle Language="En">Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>277</ChapterFirstPage>
          <ChapterLastPage>286</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>5</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_25" CorrespondingAffiliationID="Aff1_25">
              <AuthorName DisplayOrder="Western">
                <GivenName>Joel</GivenName>
                <GivenName>B.</GivenName>
                <FamilyName>Nelson</FamilyName>
              </AuthorName>
              <Contact>
                <Email>nelsonjb@UPMC.EDU</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_25">
              <OrgDivision>Department of Urology</OrgDivision>
              <OrgName>University of Pittsburgh</OrgName>
              <OrgAddress>
                <City>Pittsburgh</City>
                <State>PA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_25" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">New, effective therapies for castration-resistant prostate cancer are needed to treat this lethal form of the disease. Through an understanding of the biology of endothelin-1 and the endothelin receptors (the endothelin axis) in prostate cancer, this axis has emerged as a promising target for therapeutic intervention. Clinical trials of potent, selective, or specific endothelin receptor A subtype (ET<Subscript>A</Subscript>) antagonists have demonstrated clinical activity, but such agents have not yet been approved for the treatment of prostate cancer. These generally well-tolerated, oral agents are ideal for chronic administration. This chapter will discuss the biology of the endothelin axis, several of the preclinical observations supporting the therapeutic rationale, and some of the available clinical trial data on this promising new approach.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Bone metastases</Keyword>
            <Keyword>Clinical trials</Keyword>
            <Keyword>Endothelin receptors</Keyword>
            <Keyword>Endothelin-1</Keyword>
            <Keyword>Prostate cancer</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>The Endothelin Axis</Heading>
            <Para TextBreak="No">As a PhD project, a graduate student named Masashi Yanagisawa published a seminal paper in the journal Nature about the isolation and characterization of a new, 21-residue peptide produced by porcine aortic endothelial cells, called endothelin [<CitationRef CitationID="CR1_25">1</CitationRef>]. Endothelin is the most potent vasoconstrictor identified, at least ten times more potent than angiotensin II, and 100 times more potent, on a molar basis, than norepinephrine. Since its discovery in 1988, there have been over 21,000 publications listing endothelin as a key word in the scientific literature. This peptide, now referred to as endothelin 1 (ET-1) (Fig. <InternalRef RefID="Fig1">25.1</InternalRef>), is part of a family of similar peptides including ET-2, ET-3, and the sarafotoxins (isolated from the venom of the Israeli Burrowing Asp, atractaspis engaddensis) [<CitationRef CitationID="CR2_25">2</CitationRef>]. The 21 amino acid, active form of ET-1 is derived from a 39-amino acid precursor peptide, “big ET-1,” following proteolytic cleavage of the C-terminal portion of the molecule by an endothelin-converting enzyme [<CitationRef CitationID="CR3_25">3</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 25.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Amino acid structure of endothelin-1 (ET-1). From Nelson [<CitationRef CitationID="CR50_25">50</CitationRef>]. With kind permission from Elsevier</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_25">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_25_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">There are two endothelin receptors: endothelin receptor A (ET<Subscript>A</Subscript>) and endothelin receptor B (ET<Subscript>B</Subscript>), which are the members of the seven-transmembrane-segment G-protein-coupled superfamily. ET<Subscript>A</Subscript> has a higher affinity to ET-1 and ET-2, and less for ET-3. ET<Subscript>B</Subscript> binds all three endothelin ligands identically and plays an important role in ligand clearance. This differential function of the ET<Subscript>A</Subscript> and ET<Subscript>B</Subscript> receptors may be important in the activity of endothelin receptor antagonists as therapeutic agents. Although selective antagonists for the ET<Subscript>A</Subscript> receptor have been developed, many also bind to the ET<Subscript>B</Subscript> receptor; ET<Subscript>A</Subscript>-specific or “pure” antagonists, such as ZD4054, do not bind to the ET<Subscript>B</Subscript> receptor. Collectively, the ET family ligands and the ET receptors are termed the “ET axis.”</Para>
            <Para TextBreak="No">Originally isolated from endothelial cells, it is now recognized that ET-1 is produced by a large variety of cells from a wide range of species: ET-1 has been identified in plasma, cerebrospinal fluid, urine, breast milk, and amniotic fluid [<CitationRef CitationID="CR4_25">4</CitationRef>]. An immunoreactive form of ET-1 was found in very large quantity in human seminal fluid from both intact and vasectomized men, where the testicular contribution to the ejaculate has been eliminated, indicating a prostatic and/or seminal vesicle source [<CitationRef CitationID="CR5_25">5</CitationRef>]. Indeed, the concentrations of ET-1 in the ejaculate are amongst the highest reported in any body fluid.</Para>
            <Para TextBreak="No">Prostatic luminal epithelial cells produce ET-1, and it has been suggested that ET-1 may contribute to the contractility of the prostate stroma [<CitationRef CitationID="CR6_25">6</CitationRef>, <CitationRef CitationID="CR7_25">7</CitationRef>]. ET-1 has a mitogenic effect on cultured smooth muscle cells from a human prostate [<CitationRef CitationID="CR8_25">8</CitationRef>]. The action of ET-1 on the prostate may be paracrine since both ET<Subscript>A</Subscript> and ET<Subscript>B</Subscript> receptors have been identified in the normal human prostate [<CitationRef CitationID="CR6_25">6</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Endothelin-1 in Prostate Cancer</Heading>
            <Para TextBreak="No">The difference in concentration of ET-1 in seminal fluid when compared with plasma is of a magnitude reminiscent of prostate-specific antigen (PSA), where concentrations in the semen are measured in the milligram range compared with nanogram quantities in circulation. Just as men with advanced prostate cancer have markedly elevated levels of PSA, was it possible that ET-1 levels would be increased in a similar fashion? To test this hypothesis, ET-1 plasma levels were measured in men with castration-resistant prostate cancer (CRPC) and compared with those from men with clinically localized disease and those without prostate cancer: as a group, men with CRPC had significantly higher ET-1 levels [<CitationRef CitationID="CR9_25">9</CitationRef>]. This increase in plasma ET-1 may only be the tip of the iceberg: local tissue concentrations of ET-1 are believed to be several fold higher than levels in circulation (where ET-1 half-life is 3.5 min), because of the homeostatic mechanisms controlling the concentrations of this most potent peptide [<CitationRef CitationID="CR10_25">10</CitationRef>]. The increase in ET-1 associated with CRPC may also reflect the loss of the expression and activity of the enzyme responsible for its cleavage, neutral endopeptidase 24.11 (NEP). In androgen-independent prostate cancer cell lines and prostate cancer samples from androgen ablated men, NEP is markedly reduced [<CitationRef CitationID="CR11_25">11</CitationRef>]. Every prostate cancer cell line studied expressed ET-1 mRNA and produced the protein [<CitationRef CitationID="CR12_25">12</CitationRef>]. In human tissue samples, ET-1 specific immunohistochemistry was observed in every primary prostate cancer and in primary and metastatic lesions obtained at autopsy from men dying from CRPC, and ET-1 expression was present almost without exception [<CitationRef CitationID="CR13_25">13</CitationRef>].</Para>
            <Para TextBreak="No">Secretion of ET-1 was also increased by cytokines and growth factors active in prostate stroma–epithelium interactions. Both ET-1 and its precursor big ET-1 were produced in greater quantities by the human PC3 and DU145 human prostate cancer cell lines in response to stimulation with interleukin-1α, interleukin-1β, tumor necrosis factor, transforming growth factor β-1, or epidermal growth factor [<CitationRef CitationID="CR12_25">12</CitationRef>, <CitationRef CitationID="CR14_25">14</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Endothelin Receptors in Prostate Cancer</Heading>
            <Para TextBreak="No">In the normal prostate, both ET<Subscript>A</Subscript> and ET<Subscript>B</Subscript> receptors are expressed and are functional. Reflecting a tissue distribution seen in other organs – where ET<Subscript>A</Subscript> receptors are concentrated in the stroma and ET<Subscript>B</Subscript> receptors are concentrated on luminal cells – ET<Subscript>A</Subscript> binding has been found predominant in the stromal component of the prostate, whereas ET<Subscript>B</Subscript> binding is predominant in epithelial luminal cells [<CitationRef CitationID="CR15_25">15</CitationRef>]. However, unlike normal prostate epithelial cells, no ET<Subscript>B</Subscript> binding could be detected in human prostate cancer cell lines [<CitationRef CitationID="CR13_25">13</CitationRef>]. This down regulation of ET<Subscript>B</Subscript> receptor expression may reflect frequent somatic methylation of the ET<Subscript>B</Subscript> receptor gene, <Emphasis Type="Italic">EDNRB</Emphasis>, observed in prostate cancer and, now, in a variety of malignancies. A CpG-rich sequence, referred to as a CpG island, is embedded in the 5′ regulatory region in <Emphasis Type="Italic">EDNRB</Emphasis>: somatic methylation of CpG islands in regulatory regions of genes has been associated with decreased transcriptional activity. In an initial study, this hypermethylation was found in 5/5 human prostate cancer cell lines, 15/21 primary prostate cancer tissues, and 8/14 prostate cancer metastases, or about 70% of the total number of samples examined [<CitationRef CitationID="CR16_25">16</CitationRef>]. In subsequent studies, <Emphasis Type="Italic">EDNRB</Emphasis> methylation was found to be associated with increased prostate cancer stage and grade [<CitationRef CitationID="CR17_25">17</CitationRef>]. <Emphasis Type="Italic">EDNRB</Emphasis> hypermethylation was not observed in normal tissues using southern-blot analysis but others have observed <Emphasis Type="Italic">EDNRB</Emphasis> methylation in benign prostatic hyperplasia (BPH) tissues using a more sensitive polymerase chain reaction approach, indicating the methylation status is not specific for prostate cancer and, therefore, would not be useful as a prostate cancer biomarker [<CitationRef CitationID="CR16_25">16</CitationRef>, <CitationRef CitationID="CR18_25">18</CitationRef>]. <Emphasis Type="Italic">EDNRB</Emphasis> hypermethylation has also been observed in colon and bladder cancers, nasopharyngeal carcinoma, and lung cancer, suggesting ET<Subscript>B</Subscript> silencing may have a more global role in carcinogenesis [<CitationRef CitationID="CR19_25">19</CitationRef>–<CitationRef CitationID="CR21_25">21</CitationRef>].</Para>
            <Para TextBreak="No">Increased ET<Subscript>A</Subscript> expression has been associated with progression of prostate cancer. In the Dunning prostate cancer system, ET<Subscript>A</Subscript> receptor binding was sevenfold higher in the metastatic MLL clone and threefold higher in the tumorigenic but nonmetastatic AT-1 clone, when compared with the nontumorigenic G clone [<CitationRef CitationID="CR22_25">22</CitationRef>]. ET<Subscript>A</Subscript> expression by immunohistochemisty was studied in 51 human specimens: 71% were positive for ET<Subscript>A</Subscript> expression, which increased to 100% in patients with bone metastasis. Gleason score 8–10 had particularly high rates of ET<Subscript>A</Subscript> staining as did those cancer cells penetrating the prostatic capsule [<CitationRef CitationID="CR23_25">23</CitationRef>]. In a larger study examining 140 primary prostate cancers, high ET<Subscript>A</Subscript> expression was observed in 72% of samples and this expression was significantly elevated with increased pathological stage and grade. Patients with PSA recurrence after prostatectomy had significantly greater ET<Subscript>A</Subscript> expression in their primary tumors than did patients who were disease-free at 5 years [<CitationRef CitationID="CR24_25">24</CitationRef>]. These findings suggest that the expression of the endothelin receptors may be useful prognosticators in prostate cancer and, importantly, guide selection of those who may benefit from receptor blockade.</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Effects of Endothelin on Cancer Cells In Vitro</Heading>
            <Para TextBreak="No">ET-1 is expressed by many epithelial carcinomas, and, in particular, those associated with a local desmoplastic stromal response (pancreatic, colon, breast, etc.) [<CitationRef CitationID="CR25_25">25</CitationRef>]. In addition, some cancer cells proliferated in a dose-dependent manner when stimulated by ET-1, most notably ovarian carcinoma, suggesting autocrine activity [<CitationRef CitationID="CR26_25">26</CitationRef>, <CitationRef CitationID="CR27_25">27</CitationRef>]. Although ET-1 had a mitogenic effect in prostate cancer cell lines, the response was weak [<CitationRef CitationID="CR9_25">9</CitationRef>, <CitationRef CitationID="CR13_25">13</CitationRef>]. The combination ET-1 and polypeptide growth factors, such as epidermal growth factor, greatly increased cellular proliferation compared with either factor alone [<CitationRef CitationID="CR28_25">28</CitationRef>]. This synergistic growth effect may be the result of transactivation of the peptide growth factor signaling pathway by ET-1 [<CitationRef CitationID="CR29_25">29</CitationRef>].</Para>
            <Para TextBreak="No">It has been postulated that defects in apoptosis are the central mechanism of CRPC progression. ET-1 inhibits apoptosis in a variety of benign and malignant cell lines, including prostate cancer. For example, treatment of the rat prostate cancer cell line MLL with paclitaxel easily induced apoptosis, but in the presence of ET-1, the amount of cell death is significantly reduced [<CitationRef CitationID="CR22_25">22</CitationRef>]. This anti-apoptosis effect of ET-1 is blocked by ET<Subscript>A</Subscript> receptor antagonists, indicating that this is an ET<Subscript>A</Subscript> receptor-mediated effect. In the human prostate cancer cell line PPC-1 transfected with an ET<Subscript>A</Subscript>-over expression vector, ET-1 inhibited apoptosis in response to either paclitaxel or docetaxel, an effect blocked by an ET<Subscript>A</Subscript> receptor antagonist [<CitationRef CitationID="CR30_25">30</CitationRef>]. In vivo, the combination of an ET<Subscript>A</Subscript> receptor antagonist and docetaxel significantly inhibited tumor growth compared either with agent administered alone or with untreated controls. These findings have been supported by similar observations in other prostate cancer models using the combination of docetaxel and ET<Subscript>A</Subscript> receptor antagonists, both in vitro and in vivo [<CitationRef CitationID="CR31_25">31</CitationRef>]. Likewise, ET<Subscript>A</Subscript> receptor antagonists potentiate the cytotoxic effects of hypoxia-inducible factor inhibitor 2-methoxyestradiol in prostate cancer [<CitationRef CitationID="CR32_25">32</CitationRef>]. Collectively, these data strongly support the conduct of clinical trials examining the effects of combining ET<Subscript>A</Subscript> receptor antagonists with certain cytotoxic chemotherapeutic agents.</Para>
            <Para TextBreak="No">What is the mechanism of ET-1-induced inhibition of apoptosis? ET-1 induces the expression of AKT, leading to the phosphorylation and inactivation of the proapoptotic protein, Bad [<CitationRef CitationID="CR33_25">33</CitationRef>]. ET-1 also reduced the expression of the proapoptotic proteins Bad, Bak, or Bax. On the contrary, reexpression of ET<Subscript>B</Subscript> in prostate cancer induces apoptosis, increases expression of the same proapoptotic proteins, and increases sensitivity to paclitaxel.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Endothelin Axis and Bone Metastases</Heading>
            <Para TextBreak="No">The classic response of bone to metastatic prostate cancer is mediated by osteoblasts. ET-1 is a potent stimulator of osteoblasts. Osteoblasts have high affinity ET<Subscript>A</Subscript> receptors, at a density (∼10<Superscript>5</Superscript> per cell) greatly exceeding the density on prostate cancer cells [<CitationRef CitationID="CR34_25">34</CitationRef>]. The original hypothesis that ET-1 had a role in prostate cancer progression was largely based on its known effects on osteoblasts, as shown in a new-bone-forming model [<CitationRef CitationID="CR9_25">9</CitationRef>]. In an osteoblastic tumor model using the WISH cell line (a transformed human amnion cell line that induces a robust osteoblastic response), it was found that WISH produces large amounts of ET-1. Stable transfection of WISH with an ET-1 over expression cDNA construct generated clones producing 18-fold more bioactive ET-1. In this model, these ET-1-overexpressing clones produced significantly more new bone when implanted in the lower leg of nu/nu mice [<CitationRef CitationID="CR35_25">35</CitationRef>]. These areas of new bone formation were significantly decreased in animals treated with a selective ET<Subscript>A</Subscript> receptor antagonist. These findings have been supported by another in vivo model system, indicating the causal role of ET-1 in the pathogenesis of osteoblastic bone metastases in a breast carcinoma model [<CitationRef CitationID="CR36_25">36</CitationRef>]. Animals receiving an ET<Subscript>A</Subscript> receptor antagonist had significantly less osteoblastic lesions than controls.</Para>
            <Para TextBreak="No">The possible role of ectopically secreted ET-1 from metastatic prostate cancer cells as an important factor in tumor growth in the bone microenvironment has led to a “vicious cycle” hypothesis of disease progression (Fig. <InternalRef RefID="Fig2">25.2</InternalRef>). In this model, ET-1 stimulates the proliferation of osteoblasts, the deposition of new bone, and promotes the development of the osteoblastic lesion. In an attempt to maintain normal bone homeostasis, osteoclasts are activated to resorb bone. Since bone is a rich source of growth factors, this resorption releases these factors, making them accessible to prostate cancer cells and promoting their further growth. The use of ET<Subscript>A</Subscript> receptor antagonists has been proposed as one mechanism to break this cycle.<Figure Category="Standard" Float="Yes" ID="Fig2">
                <Caption Language="En">
                  <CaptionNumber>Fig. 25.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Prostate cancer and bone interactions. This “vicious cycle” where ET-1 acting through the ET<Subscript>A</Subscript> receptor stimulates osteoblasts, which, in turn, activate osteoclasts. The resorption of bone releases bone-derived growth factors, which stimulate prostate cancer proliferation. Strategic use of an ET<Subscript>A</Subscript> receptor antagonist is one mechanism to block this cycle. From Nelson [<CitationRef CitationID="CR50_25">50</CitationRef>]. With kind permission from Elsevier</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO2_25">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_25_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>ET Axis and Pain</Heading>
            <Para TextBreak="No">The bite of the Israeli Burrowing Asp induces a dramatic local and systemic response, an effect mediated by the sarafotoxins within the venom. Since the sarafotoxins are members of the endothelin family, it is not surprising that ET-1 induces hyperalgesia and pain in a variety of model systems, including a dramatic pain response in a man undergoing infusion of ET-1 into a brachial artery [<CitationRef CitationID="CR37_25">37</CitationRef>]. Men with advanced prostate cancer suffer considerably from tumor-induced pain, particularly in association with bone metastases: it is possible that some of the pain they experience is due to local ET-1 secretion by prostate cancer cells.</Para>
            <Para TextBreak="No">The mechanistic pattern of ET-1 induced pain appeared to be novel and unresponsive at usual doses to cyclooxygenase inhibitors such as indomethicin or ibuprofen, suggesting that agents specifically targeting ET-1 activity, such as ET<Subscript>A</Subscript> antagonists, could be useful in alleviating pain [<CitationRef CitationID="CR38_25">38</CitationRef>]. As a mediator of pain, ET-1, acting through the ET<Subscript>A</Subscript> receptor, had both direct effects on nerves and as a potentiator of other noxious stimuli [<CitationRef CitationID="CR39_25">39</CitationRef>]. In a new murine model of cancer pain, ET-1-producing tumors created within bone were significantly more painful than other, non-ET-1-producing tumors: local administration of an ET<Subscript>A</Subscript> receptor antagonist significantly blocked this effect [<CitationRef CitationID="CR40_25">40</CitationRef>].</Para>
            <Para TextBreak="No">On the basis of the preclinical findings described earlier and the availability of potent and selective ET<Subscript>A</Subscript> receptor antagonists, it was both reasonable and strategic to target ET-1 induced in men with prostate cancer [<CitationRef CitationID="CR9_25">9</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Atrasentan (ABT-627)</Heading>
            <Para TextBreak="No">Abbott Laboratories was one of the many pharmaceutical companies looking for new agents for cardiovascular disease, and developed ABT-627, which, at the time of disclosure, was the most potent and selective ET<Subscript>A</Subscript> receptor antagonist described. ABT-627, or atrasentan, is a highly potent (Ki = 0.034 nM) and selective (1,800-fold) ET<Subscript>A</Subscript> receptor antagonist, blocking the biological effects of ET-1 in a host of in vitro and in vivo model systems [<CitationRef CitationID="CR41_25">41</CitationRef>, <CitationRef CitationID="CR42_25">42</CitationRef>]. Atrasentan was developed as an orally bioavailable agent with a half-life of 25 h, favoring once-per-day dosing. Single-dose pharmacokinetic studies with atrasentan in normal male volunteers demonstrated a terminal half-life range of 20–25 h with extensive tissue distribution. Consistent with its vasoactive nature, the most frequent adverse events were transient headache, rhinitis, and nausea. As seen throughout the subsequent trials in cancer, atrasentan did not induce hepatic or hematological toxicity [<CitationRef CitationID="CR43_25">43</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Atrasentan: Phase I Trials</Heading>
            <Para TextBreak="No">Two phase I clinical trials were performed to assess the safety and pharmacokinetics of atrasentan in men with CRPC and other patients with refractory adenocarcinomas [<CitationRef CitationID="CR40_25">44</CitationRef>, <CitationRef CitationID="CR44_25">45</CitationRef>]. In both studies, patients were treated for 28 days with escalating oral atrasentan doses (2.5–95 mg) and were then eligible for an extension study. Similar to the phase I studies in normal males, the most common side effects were headache, rhinitis, and peripheral edema. In one trial, dose-limiting toxicity (headache) was seen at 75 mg [<CitationRef CitationID="CR44_25">44</CitationRef>]: in the other study, no maximum tolerated dose was found in the dose range studied (up to 95 mg) [<CitationRef CitationID="CR45_25">45</CitationRef>].</Para>
            <Para TextBreak="No">In men with CRPC, the PSA level was unchanged or dropped in 68% (15/22) during the 28-day exposure, with declines ranging from 5 to 95%. There was no obvious correlation between dose and PSA declines. In seven out of ten patients (70%) with narcotic-requiring pain, atrasentan reduced pain, as measured by the visual analog scale. These results, although not placebo-controlled and from short, open-label trials, were nevertheless compelling.</Para>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Atrasentan: Phase II Trials in Prostate Cancer</Heading>
            <Section2 ID="Sec10">
              <Heading>
                <Emphasis>M96-500</Emphasis>
              </Heading>
              <Para TextBreak="No">On the basis of the preclinical findings implicating ET-1 in pain and the reduction in pain observed in some patients in the phase I clinical trials, a phase II trial was designed to study atrasentan in relieving prostate-cancer induced pain. In this double-blind, placebo-controlled study, 131 men with castration-resistant metastatic prostate cancer with disease-related pain requiring opioid analgesics were enrolled in three study groups: 43 were randomized to the placebo arm, 40 were randomized to the atrasentan 2.5 mg arm, and 48 were randomized to the atrasentan 10 mg arm. Eighty-one subjects (62%) discontinued study drug before the planned 84 days of treatment, reflecting high rates of disease progression. There was no statistically significant difference in response rates between placebo and atrasentan for the primary endpoint (pain relief at week 12). There was, however, a trend toward improvement in pain without increased analgesic consumption in atrasentan-treated patients: the average VAS pain score for subjects receiving atrasentan 10 mg decreased 8% from baseline, while the average VAS pain score for placebo subjects increased 8% from baseline. Statistically significant improvement was seen for the atrasentan 10 mg group vs. placebo (<Emphasis Type="Italic">p</Emphasis> ≤ 0.05) at week 12 for two pain domains in the brief pain inventory (BPI): pain interference with relations with other people (<Emphasis Type="Italic">p</Emphasis>= 0.031), and worst pain in the last 24 h (<Emphasis Type="Italic">p</Emphasis>= 0.030).</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>M96-594</Heading>
              <Para TextBreak="No">The efficacy of atrasentan in delaying disease progression was studied in a double-blind placebo-controlled Phase II trial in men with asymptomatic, hormone-refractory, metastatic prostate cancer [<CitationRef CitationID="CR46_25">46</CitationRef>]. In this international study, 288 men were randomized to receive daily oral doses of placebo, atrasentan 2.5 or 10 mg. The primary endpoint was time to disease progression, defined as new lesions, pain requiring opioids, disease-related symptoms requiring intervention. Secondary endpoints included time to PSA progression, changes in bone markers, and quality of life. Median time to disease progression was 183 days in the atrasentan 10 mg treated patients compared with 137 days for the placebo group (<Emphasis Type="Italic">p</Emphasis>= 0.13) in the intent-to-treat population. In the evaluable subset (<Emphasis Type="Italic">n</Emphasis> = 244), there was a significant (<Emphasis Type="Italic">p</Emphasis>= 0.021) delay in disease progression from 129 days (placebo) to 196 days (atrasentan 10 mg). There was a significant (<Emphasis Type="Italic">p</Emphasis>= 0.002) delay in PSA progression in the atrasentan 10 mg group: median time to PSA progression was more than twice (155 days) that of placebo (71 days). As observed in the previous trials, atrasentan was well tolerated, with headache, edema, and rhinitis being the most common side effects. Men reaching an endpoint were permitted to enter an open-label atrasentan study: this design with significant placebo crossover confounds any survival analysis. Markers of bone deposition (alkaline phosphatase, bone alkaline phosphatase) and bone resorption (N-telopeptides, C-telopeptides, and deoxypyridinoline) were also studied in this trial, based on the preclinical data implicating the ET axis in the osteoblastic response of bone to cancer [<CitationRef CitationID="CR47_25">47</CitationRef>]. At baseline, there were significant elevations in markers of both bone deposition and bone resorption, ranging from 1.4 to 2.7-fold above normal. Men on placebo had significant (<Emphasis Type="Italic">p</Emphasis>&lt; 0.001) increases in both sets of markers, consistent with disease progression. In a dose-dependent fashion, men on atrasentan had a stabilization of these markers suggesting a disruption in the expected progression in bony sites. These finding were the first strong indication that atrasentan may be most active in men with bone-metastatic prostate cancer.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Atrasentan: Phase III Trials in Prostate Cancer</Heading>
            <Section2 ID="Sec13">
              <Heading>M00-211</Heading>
              <Para TextBreak="No">A phase III trial of atrasentan was designed to essentially duplicate the time to disease progression phase II trial (M96-594), with a few notable differences. Given the increased response rate in the 10 mg atrasentan without an increase in side effects, the phase III trial had only placebo and 10 mg arms. The second difference was a mandated objective evaluation of disease progression to reduce, as much as possible, PSA bias. Therefore, unlike the phase II study, where radiographic imaging was performed for clinical indications only, in the phase 3 M00-211 study, bone scans and axial imaging were performed every 3 months. The primary endpoint (disease progression), secondary endpoints (PSA progression, markers of bone metabolism, quality of life), enrollment criteria (asymptomatic, metastatic CRPC) were otherwise the same.</Para>
              <Para TextBreak="No">In this multinational trial, a total of 809 men were enrolled (401 placebo, 408 atrasentan 10 mg) [<CitationRef CitationID="CR48_25">48</CitationRef>]. Atrasentan did not reduce the risk of disease progression relative to placebo (HR, 0.89; 95% confidence interval, 0.76–1.04; <Emphasis Type="Italic">p</Emphasis>= 0.136) (Fig. <InternalRef RefID="Fig3">25.3</InternalRef>). The perprotocol analysis (329 placebo, 342 atrasentan 10 mg) was significantly in favor of atrasentan 10 mg (HR 1.26; 95% confidence intervals 1.06–1.50; <Emphasis Type="Italic">p</Emphasis>= 0.007). Secondary endpoints (PSA progression, bone marker progression, and certain quality of life tools) all significantly favored atrasentan 10 mg.<Figure Category="Standard" Float="Yes" ID="Fig3">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 25.3</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Time to disease progression in a phase III study of atrasentan in men with metastatic castration-resistant prostate cancer (CRPC) (M00-211). Progression events cluster at the time of scheduled radiographic evaluations. Reproduced with permission from John Wiley &amp; Sons, copyright 2008 [<CitationRef CitationID="CR50_25">49</CitationRef>]</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO3_25">
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_25_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">In a hypothesis-generating exercise, patients were stratified based on the characteristics of their metastatic disease at enrollment (bone only, bone and soft tissue, soft tissue only) to determine whether a particular disease presentation favored better response to atrasentan. Consistent with the preclinical and earlier clinical trials, those men with bone metastases (with or without soft tissue metastases) enjoyed the most significant delays in disease progression compared with placebo-treated patients with the same characteristics. Since 85% of the men enrolled into this trial had bone metastases, this finding is pertinent to the large majority of CRPC patients, to the design of subsequent trials, and to the possible use of ET<Subscript>A</Subscript> antagonists in this clinical setting.</Para>
            </Section2>
            <Section2 ID="Sec14">
              <Heading>M00-244</Heading>
              <Para TextBreak="No">A double-blind, placebo-controlled trial (M00-244) was designed to determine whether atrasentan 10 mg can delay disease progression in men with rising PSA on hormonal therapy, but who do not yet have radiographic or clinical evidence of metastatic disease [<CitationRef CitationID="CR48_25">49</CitationRef>]. Of 941 men who met these criteria, 467 were randomized to receive atrasentan 10 mg and 474 to receive placebo. The primary endpoint was time to disease progression, defined as the onset of metastases. Secondary endpoints were time to PSA progression, change in bone alkaline phosphatase, PSA doubling time, and overall survival.</Para>
              <Para TextBreak="No">There was a 93-day delay in median time to disease progression with atrasentan compared with placebo (764 days vs. 671 days, respectively), but this difference was not significant (Fig. <InternalRef RefID="Fig4">25.4</InternalRef>). There were large geographic differences in time to disease progression: in the United States, median time to disease progression was 590 days with atrasentan, compared with 847 days at non-United States sites (Canada, Europe, Africa). A significantly higher percentage of atrasentan-treated patients discontinued prematurely compared with placebo (33.2 vs. 25.9%, respectively), an event significantly more common at United States sites (40.8%) than non-United States sites (21.9%). Atrasentan lengthened PSA doubling time and slowed the increase in bone alkaline phosphatase. Median survival was 1,477 days with atrasentan and 1,403 days with placebo: these data must be considered with caution, since 54% of placebo-treated patients subsequently enrolled in an open-label study and received atrasentan.<Figure Category="Standard" Float="Yes" ID="Fig4">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 25.4</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Time to disease progression in a phase III study of atrasentan in men with nonmetastatic CRPC (M00-244). Median time to progression was 764 days with atrasentan and 671 days with placebo (<Emphasis Type="Italic">p</Emphasis>= 0.288). Reproduced with permission from John Wiley &amp; Sons, copyright 2007 [48]</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO4_25">
                    <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_25_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
            </Section2>
            <Section2 ID="Sec15">
              <Heading>Ongoing Phase III Trial</Heading>
              <Para TextBreak="No">The Southwestern Oncology Group (SWOG) has initiated a phase III study of docetaxel and atrasentan vs. docetaxel and placebo in men with CRPC. The primary endpoint of the trial is to compare overall survival and progression-free survival between the groups. The study is designed to enroll 930 men. It opened in August 2006 with an estimated primary completion date of June 2010. The trial is supported by the multiple preclinical observations about the synergistic effects of ET<Subscript>A</Subscript> antagonists and cytotoxic chemotherapeutic agents.</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Summary</Heading>
              <Para TextBreak="No">The completed phase II and III trials of atrasentan in CRPC demonstrate a consistently modest effect favoring atrasentan. There have been repeated significant effects of atrasentan on attenuating markers of bone metabolism, supporting a mechanism of action targeting osseous prostate cancer metastases. Unfortunately, phase III trials were plagued by design (M00-211) and conduct (M00-244) flaws. Given the significant crossover of placebo-treated patients to receive atrasentan in open-label extension studies, an overall survival effect is not assessable. This final fact stands in stark contrast to the overall survival advantage recently observed in the phase II trial (Study 6) of the specific endothelin-A antagonist ZD4054, currently being developed by AstraZeneca, where crossover was not permitted [<CitationRef CitationID="CR50_25">50</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec17" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">The endothelin axis has emerged as a unique target for the treatment of castration-resistant prostate cancer, particularly for those with skeletal metastases. Preclinical studies of endothelin-1, the endothelin receptors ET<Subscript>A</Subscript> and ET<Subscript>B</Subscript>, indicate an important role in prostate cancer progression. Clinical trials of ET<Subscript>A</Subscript> antagonists in CRPC support ongoing investigations of these agents. The consistency of findings in preclinical models and in phase I, phase II, and phase III clinical trials all support an ongoing investigation of agents designed to disrupt this axis. Although many questions remain unanswered, the ongoing phase III clinical trials will provide insights into the real benefits of this approach.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_25.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Acknowledgments>
            <Heading>Acknowledgment</Heading>
            <SimplePara>Chapter reprinted from Nelson [<CitationRef CitationID="CR51_25">51</CitationRef>]. With kind permission from Elsevier.</SimplePara>
          </Acknowledgments>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_25">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yanagisawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kurihara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kimura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1988</Year>
                <ArticleTitle Language="En">A novel potent vasoconstrictor peptide produced by vascular endothelial cells</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>332</VolumeID>
                <FirstPage>411</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>2451132</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/332411a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1cXlsVaks78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_25">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Inoue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yanagisawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kimura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>2863</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>2649896</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.86.8.2863</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXkslahsLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989;86:2863–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_25">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kimura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Kasuya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sawamura</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1989</Year>
                <ArticleTitle Language="En">Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure–activity relationships of big endothelin-1</ArticleTitle>
                <JournalTitle>J Cardiovasc Pharmacol</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>Suppl 5</IssueID>
                <FirstPage>S5</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>2473327</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00005344-198900135-00003</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXktlektLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kimura S, Kasuya Y, Sawamura T, et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure–activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989;13 Suppl 5:S5–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_25">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Battistini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>D’Orleans-Juste</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Sirois</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids</ArticleTitle>
                <JournalTitle>Lab Invest</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>600</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>8515652</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXmt1aqs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Battistini B, D’Orleans-Juste P, Sirois P. Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_25">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Casey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Byrd</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>MacDonald</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Massive amounts of immunoreactive endothelin in human seminal fluid</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>74</VolumeID>
                <FirstPage>223</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>1727824</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.74.1.223</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xit1yqsLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 1992;74:223–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_25">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Prayer-Galetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Rossi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Belloni</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>157</VolumeID>
                <FirstPage>2334</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9146666</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64776-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsVehtrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prayer-Galetti T, Rossi GP, Belloni AS, et al. Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J Urol 1997;157:2334–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_25">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lagenstroer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Tang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Shapiro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Divish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Opgenorth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lepor</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>150</VolumeID>
                <IssueID>2 Pt 1</IssueID>
                <FirstPage>495</FirstPage>
                <LastPage>9</LastPage>
              </BibArticle>
              <BibUnstructured>Lagenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 1993;150(2 Pt 1):495–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_25">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Saita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Yazawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Koizumi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells</ArticleTitle>
                <JournalTitle>Eur J Pharmacol</JournalTitle>
                <VolumeID>349</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9669505</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0014-2999(98)00183-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjsVehtLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saita Y, Yazawa H, Koizumi T, et al. Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur J Pharmacol 1998;349:123–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_25">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Hedican</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>944</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7585222</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0995-944</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnvVyrtb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_25">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Opgenorth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Fleisher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Frank</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Perioperative plasma endothelin-1 and big endothelin-1 concentrations in elderly patients undergoing major surgical procedures</ArticleTitle>
                <JournalTitle>Anesth Analg</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>898</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="PID">
                  <Handle>10195544</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3gvF2iuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Opgenorth TJ, Fleisher LA, Frank SM. Perioperative plasma endothelin-1 and big endothelin-1 concentrations in elderly patients undergoing major surgical procedures. Anesth Analg 1999;88:898–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_25">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CN</Initials>
                  <FamilyName>Papandreou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Usmani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Geng</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>50</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9427606</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0198-050</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjt1Ggtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_25">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Granchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Brocchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Bonaccorsi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>267</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>11746273</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10022</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjvVektA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001;49:267–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_25">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chan-Tack</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Hedican</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>663</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8630991</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhtVClsrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_25">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Brun</FamilyName>
                  <Particle>Le</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Aubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Soliman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Upregulation of endothelin 1 and its precursor by IL-1a, TNF-a, and TGF-B in the PC3 human prostate cancer cell line</ArticleTitle>
                <JournalTitle>Cytokine</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>157</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>10089138</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1006/cyto.1998.0407</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1a, TNF-a, and TGF-B in the PC3 human prostate cancer cell line. Cytokine 1999;11:157–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_25">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kobayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Tang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Wand</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Localization of endothelin receptors in the human prostate</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>151</VolumeID>
                <FirstPage>763</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8309002</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7kt1SmtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kobayashi S, Tang R, Wand B, et al. Localization of endothelin receptors in the human prostate. J Urol 1994;151:763–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_25">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W-H</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Nguyen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>35</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8988036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjvFentQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Lee W-H, Nguyen SH, et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997;57:35–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_25">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yegnasubramanian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kowalski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Gonzalgo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Hypermethylation of CpG islands in primary and metastatic human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>1975</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>15026333</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-03-3972</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitFCgtLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_25">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Jeronimo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Henrique</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Campos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Endothelin B receptor gene hypermethylation in prostate adenocarcinoma</ArticleTitle>
                <JournalTitle>J Clin Pathol</JournalTitle>
                <VolumeID>56</VolumeID>
                <FirstPage>52</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>12499435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1136/jcp.56.1.52</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3s%2FitFGmtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jeronimo C, Henrique R, Campos PF, et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003;56:52–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_25">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Pao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tsutsumi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Uzvolgy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FA</Initials>
                  <FamilyName>Gonzales</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>903</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>11309363</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/10.9.903</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsVels7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pao MM, Tsutsumi M, Liang G, Uzvolgy E, Gonzales FA, Jones PA. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001;10:903–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_25">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K-W</Initials>
                  <FamilyName>Lo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y-S</Initials>
                  <FamilyName>Tsang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kwong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K-F</Initials>
                  <FamilyName>To</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PML</Initials>
                  <FamilyName>Teo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>651</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.10271</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lo K-W, Tsang Y-S, Kwong J, To K-F, Teo PML, Huang DP. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 2002;95:651–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_25">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Belinsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Franklin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Beard</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Molecular and physiologic evidence for 5′ CpG island methylation of the endothelin B receptor gene in lung cancer</ArticleTitle>
                <JournalTitle>Chest</JournalTitle>
                <VolumeID>121</VolumeID>
                <FirstPage>27S</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11893663</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1378/chest.121.3_suppl.27S</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cohen AJ, Belinsky S, Franklin W, Beard S. Molecular and physiologic evidence for 5′ CpG island methylation of the endothelin B receptor gene in lung cancer. Chest 2002;121:27S–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_25">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Godara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Cannon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GM</Initials>
                  <FamilyName>Cannon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RR</Initials>
                  <FamilyName>Bies</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Pflug</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>27</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>15800935</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20252</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFSns73P</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Godara G, Cannon GW, Cannon GM, Bies RR, Nelson JB, Pflug B. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005;65:27–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_25">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Gohji</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kitazawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Tamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Katsuoka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakajima</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of endothelin receptor A associated with prostate cancer progression</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>165</VolumeID>
                <FirstPage>1033</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11176535</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)66597-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhsVWqtbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001;165:1033–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_25">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Godara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Pecher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Jukic</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Distinct patterns of endothelin axis expression in primary prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>70</VolumeID>
                <FirstPage>209</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>17656249</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2007.03.017</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Godara G, Pecher S, Jukic DM, et al. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 2007;70:209–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_25">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kusuhara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yamaguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nagasaki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1990</Year>
                <ArticleTitle Language="En">Production of endothelin in human cancer cell lines</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>50</VolumeID>
                <FirstPage>3257</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>2185884</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXktlyhurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kusuhara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_25">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schichiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hirata</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Nakajima</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>87</VolumeID>
                <FirstPage>1867</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1172/JCI115210</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87:1867–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_25">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bagnato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Battistini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Nisen</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The endothelin axis: emerging role in cancer</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>110</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12563310</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc990</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXisVCqsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_25">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Littlewood</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors</ArticleTitle>
                <JournalTitle>Biochem J</JournalTitle>
                <VolumeID>263</VolumeID>
                <FirstPage>977</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>2557015</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXmt1Kjsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brown KD, Littlewood CJ. Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors. Biochem J 1989;263:977–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_25">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Daub</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FU</Initials>
                  <FamilyName>Weiss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Wallasch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ullrich</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>379</VolumeID>
                <FirstPage>557</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>8596637</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/379557a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhtVWhtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_25">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Akhavan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>McHugh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Guruli</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Endothelin receptor A blockade enhances taxane effects in prostate cancer</ArticleTitle>
                <JournalTitle>Neoplasia</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>725</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>16984730</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1593/neo.06388</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVGltbnL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Akhavan A, McHugh KH, Guruli G, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8:725–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_25">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Banerjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>3818</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>17440096</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-3879</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXkt1KitLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67:3818–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_25">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Mabjeesh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Shefler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Amir</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Matzkin</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>679</FirstPage>
                <LastPage>89</LastPage>
                <Occurrence Type="PID">
                  <Handle>18288682</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20734</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXms1Wis7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mabjeesh NJ, Shefler A, Amir S, Matzkin H. Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. Prostate 2008;68:679–89.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_25">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Udan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Guruli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Pflug</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Endothelin-1 inhibits apoptosis in prostate cancer</ArticleTitle>
                <JournalTitle>Neoplasia</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>631</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16026642</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1593/neo.04787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXps1Cnt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7:631–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_25">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Takuwa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Ohue</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Takuwa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yamashita</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Endothelin-1 activiates phospholipase C and mobilizes Ca<Superscript>++</Superscript>from extra- and intracellular pools in osteoblastic cells</ArticleTitle>
                <JournalTitle>Am J Physiol</JournalTitle>
                <VolumeID>257</VolumeID>
                <FirstPage>E797</FirstPage>
                <LastPage>803</LastPage>
                <Occurrence Type="PID">
                  <Handle>2558572</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXpt1CrsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 activiates phospholipase C and mobilizes Ca<Superscript>++</Superscript>from extra- and intracellular pools in osteoblastic cells. Am J Physiol 1989;257:E797–803.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_25">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Nguyen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Wu-Wong</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>1063</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10223507</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(98)00658-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3jvVSiug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_25">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Yin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Mohammad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>KaKonen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A causal role of endothelin-1 in the pathogenesis of osteoblastic bone metastases</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>100</VolumeID>
                <FirstPage>10954</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12941866</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.1830978100</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXnslyntbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yin JJ, Mohammad KS, KaKonen SM, et al. A causal role of endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_25">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Dahlof</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gustafsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hedner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Hansson</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction</ArticleTitle>
                <JournalTitle>J Hypertens</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>811</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>2172370</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00004872-199009000-00004</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2Fjs12nsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 1990;8:811–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_25">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Raffa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Schupsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Jacoby</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model</ArticleTitle>
                <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                <VolumeID>278</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>8764328</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XktlGhur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Raffa RB, Schupsky JJ, Lee DK, Jacoby HI. Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther 1996;278:1–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_25">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Davar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Hans</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MU</Initials>
                  <FamilyName>Fareed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Sinnott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Strichartz</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve</ArticleTitle>
                <JournalTitle>Neuroreport</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>2279</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>9694215</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00001756-199807130-00025</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXltVKltrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1998;9:2279–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_25">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Peters</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Lindsay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Pomonis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Endothelin and the tumorigenic component of bone cancer pain</ArticleTitle>
                <JournalTitle>Neuroscience</JournalTitle>
                <VolumeID>126</VolumeID>
                <FirstPage>1043</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>15207337</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.neuroscience.2004.04.027</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXltVCjuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004;126:1043–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_25">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Opgenorth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Adler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SV</Initials>
                  <FamilyName>Calzadilla</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist</ArticleTitle>
                <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>473</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>8632312</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhtFaksbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276:473–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_25">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Verhaar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AY</Initials>
                  <FamilyName>Grahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AWM</Initials>
                  <FamilyName>Weerdt</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans</ArticleTitle>
                <JournalTitle>Br J Clin Pharmacol</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>562</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>10848720</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1365-2125.2000.00171.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXks1Snsb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Verhaar MC, Grahn AY, van Weerdt AWM, et al. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol 2000;49:562–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_25">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Samara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Dutta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Granneman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Dordal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Padley</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Single-dose pharmacokinetics of atrasentan, and endothelin-A receptor antagonist</ArticleTitle>
                <JournalTitle>J Clin Pharmacol</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>397</FirstPage>
                <LastPage>403</LastPage>
                <Occurrence Type="PID">
                  <Handle>11304896</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1177/00912700122010258</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXivVGkt7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ. Single-dose pharmacokinetics of atrasentan, and endothelin-A receptor antagonist. J Clin Pharmacol 2001;41:397–403.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_25">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Bowling</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>2171</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>11956279</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2002.08.028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjvVKms7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_25">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Zonnenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Groenewegen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Janus</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>2965</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>12912943</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmtF2hsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_25">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Padley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Breul</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, placebo controlled trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>679</FirstPage>
                <LastPage>89</LastPage>
                <Occurrence Type="PID">
                  <Handle>12586806</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.04.176</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVGrurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Padley RJ, Breul J, et al. The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, placebo controlled trial. J Clin Oncol 2003;21:679–89.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_25">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Nabulsi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>169</VolumeID>
                <FirstPage>1143</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12576870</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000042162.08938.27</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXht1Cms7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169:1143–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_25">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P-A</Initials>
                  <FamilyName>Abrahamsson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>110</VolumeID>
                <FirstPage>1959</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>17886253</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.22996</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlertbrP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carducci MA, Saad F, Abrahamsson P-A, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_25">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Love</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Chin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>113</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>2478</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>18785254</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.23864</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtlKru77K</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Love W, Chin JL, et al. Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone refractory prostate cancer. Cancer 2008;113(9):2478–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_25">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ND</Initials>
                  <FamilyName>James</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Zonnenberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases</ArticleTitle>
                <JournalTitle>Eur J Cancer Suppl</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>3</FirstPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1359-6349(07)70096-4</Handle>
                </Occurrence>
                <BibComments>Abstract 3LB</BibComments>
              </BibArticle>
              <BibUnstructured>James ND, Borre M, Zonnenberg B, et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. Eur J Cancer Suppl 2007;5:3. Abstract 3LB.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_25">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2009</Year>
                <ArticleTitle Language="En">Endothelin receptors as therapeutic targets in castration-resistant prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol Suppl</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>20</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eursup.2008.10.004</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhvVGgsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB. Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. Eur Urol Suppl 2009;8:20–8.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
